Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics
Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma (<i>R</i> > 0.99) and high quantitative precision, with a coefficient of variance (CV) below 10% for 80% of all peptides quantified in the group of healthy donors. All of the targets that perform well in the microsampling device also show good long-term stability when stored at room temperature for up to 232 days, further showcasing the potential benefits of collecting samples in a dry format.
Authors
- Benjamin Challis (ORCID: https://orcid.org/0000-0002-1130-2851)
- Marcus Henricsson (ORCID: https://orcid.org/0000-0002-4202-0339)
- Pia Davidsson (ORCID: https://orcid.org/0000-0002-4775-5828)
- Tasso Miliotis (ORCID: https://orcid.org/0000-0003-4917-0724)
- Andreas Hober (ORCID: https://orcid.org/0000-0001-8947-2562)
- Tim Ruckh
Institutions
- Digital China Health (China) (CN)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- Digital Health Cooperative Research Centre (AU)
Publication Details
- Journal
- Analytical Chemistry
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1021/acs.analchem.4c05455
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80